Advertisement

Topics

Expand New Drugs for TB [endTB] Observational Study

2017-08-23 18:23:21 | BioPortfolio

Summary

This observational study will examine the safety and efficacy of bedaquiline and delamanid used (individually, not together) in routine, multidrug regimens for treatment of MDR-TB. The information gathered in this study will inform doctors how best to use these TB drugs in the future.

Study Design

Conditions

Tuberculosis, Multidrug-Resistant

Intervention

This is a non-intervention observational study

Location

National Treatment Centre for Tuberculosis, Abovian, Armenia
Abovyan
Armenia
220053

Status

Recruiting

Source

Partners in Health

Results (where available)

View Results

Links

Published on BioPortfolio: 2017-08-23T18:23:21-0400

Clinical Trials [1387 Associated Clinical Trials listed on BioPortfolio]

Biomarkers for Therapy Response in Drug-resistant Tuberculosis

Multi-center, observational, prospective cohort study including patients with multidrug-resistant tuberculosis at different sites in Germany. The aim the study is the identification of bi...

The Individualized M(X) Drug-resistant TB Treatment Strategy Study

This is a randomized controlled clinical trial comparing treatment success of a gene-derived individualized drug-resistant Tuberculosis regimen to a standard Tuberculosis regimen based on ...

FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis

Drug-resistant tuberculosis is becoming a major problem for the whole humanity, and development of new Anti-TB drugs is of great importance. Since Kazakhstan is a country with the high bur...

Treatment of Tuberculosis Multidrug Resistance Treatment of Tuberculosis Multidrug Resistance

The principal objective is to provide curative treatment to patients with confirmed multidrug-resistant tuberculosis who do not respond to treatment with standard first line anti tuberculo...

Improving the Management of Drug Resistant Tuberculosis in the UK

The 'rising tide' of antimicrobial resistance is a source of concern across most infectious diseases. In the UK, for example, 6.8% of the ~8,500 tuberculosis patients seen in 2012 were res...

PubMed Articles [17672 Associated PubMed Articles listed on BioPortfolio]

Systematic Review, Meta-Analysis, and Cost Effectiveness of Treatment of Latent Tuberculosis Infection to Reduce Progression to Multidrug-Resistant Tuberculosis.

Evidence-based recommendations for treating persons having presumed latent tuberculosis infection (LTBI) after contact to infectious multidrug-resistant tuberculosis (MDR TB) are lacking because publi...

Primary multidrug-resistant tuberculosis versus drug-sensitive tuberculosis in non-HIV-infected patients: Comparisons of CT findings.

Multidrug-resistant tuberculosis has emerged as a global threat. The aim of this work was to compare the CT findings of primary multidrug-resistant tuberculosis and drug-sensitive tuberculosis in non-...

Pyridines: Multidrug-resistant tuberculosis (MDR-TB) inhibitors.

Mycobacterium tuberculosis (MTB) infection has become an increasing health threat due to the worldwide emergence of multidrug-resistant MTB (MDR-MTB) strain. Isoniazid (pyridine) resistance problem is...

Prevalence of and risk factors for multidrug-resistant tuberculosis in Iran and its neighboring countries: systematic review and meta-analysis.

Tuberculosis, in particular drug-resistant tuberculosis, is of global concern due to the high mortality and morbidity associated with it annually. The aim of this study was to determine the prevalence...

Outcomes of multidrug-resistant tuberculosis in Zambia: a cohort analysis.

The purpose of this study was to establish a baseline for measuring the impact of the programmatic management of drug-resistant TB program by following up on outcomes of all patients diagnosed with mu...

Medical and Biotech [MESH] Definitions

Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.

Tuberculosis resistant to ISONIAZID and RIFAMPIN and at least three of the six main classes of second-line drugs (AMINOGLYCOSIDES; polypeptide agents; FLUOROQUINOLONES; THIOAMIDES; CYCLOSERINE; and PARA-AMINOSALICYLIC ACID) as defined by the CDC.

A work that reports on the results of a clinical study in which participants may receive diagnostic, therapeutic, or other types of interventions, but the investigator does not assign participants to specific interventions (as in an interventional study).

A study in which observations are made before and after an intervention, both in a group that receives the intervention and in a control group that does not.

A study that uses observations at multiple time points before and after an intervention (the "interruption"), in an attempt to detect whether the intervention has had an effect significantly greater than any underlying trend over time.

More From BioPortfolio on "Expand New Drugs for TB [endTB] Observational Study"

Quick Search
Advertisement
 

Relevant Topics

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Tuberculosis TB
Tuberculosis (TB) is an infectious disease caused by bacteria belonging to the Mycobacterium tuberculosis complex. Over nine million new cases of TB, and nearly two million deaths from TB, are estimated to occur around the world every year, and new inf...


Searches Linking to this Trial